

Catherine H Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2355225/publications.pdf>

Version: 2024-02-01

238
papers

16,592
citations

13865

67
h-index

18130

120
g-index

248
all docs

248
docs citations

248
times ranked

14461
citing authors

#	ARTICLE	IF	CITATIONS
1	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-stage, adaptive placebo-controlled trial (APRICOT)*. <i>British Journal of Dermatology</i> , 2022, 186, 245-256.	1.5	22
2	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. <i>Lancet Rheumatology, The</i> , 2022, 4, e42-e52.	3.9	66
3	Differences in Clinical Features and Comorbid Burden between HLA-C*06:02 Carrier Groups in >9,000 People with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1617-1628.e10.	0.7	11
4	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.5	11
5	Genome-wide association meta-analysis identifies 29 new acne susceptibility loci. <i>Nature Communications</i> , 2022, 13, 702.	12.8	23
6	Comparison of ALitretinoin with PUVA as the first-line treatment in patients with severe chronic Hand eczema (ALPHA): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e060029.	1.9	2
7	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-106.	0.7	1
8	Response to: "Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-stage, adaptive placebo-controlled trial (APRICOT)": reply from the authors. <i>British Journal of Dermatology</i> , 2022, 186, 909-910.	1.5	3
9	Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. <i>Dermatology and Therapy</i> , 2022, 12, 195-202.	3.0	4
10	Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021—a round Delphi survey among international experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1467-1476.	2.4	14
11	Biomarkers of disease progression in people with psoriasis: a scoping review. <i>British Journal of Dermatology</i> , 2022, 187, 481-493.	1.5	22
12	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 882-893.	2.9	21
13	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. <i>British Journal of Dermatology</i> , 2022, 187, 494-506.	1.5	14
14	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266.	1.9	6
15	Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (ChiPsoCov registry). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2076-2086.	2.4	11
16	Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. <i>Lancet Rheumatology, The</i> , 2022, 4, e490-e506.	3.9	61
17	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 329-337.	2.4	13
18	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136

#	ARTICLE	IF	CITATIONS
19	The influence of 2020 coronavirus lockdown on presentation of oral and maxillofacial trauma to a central London hospital. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2021, 59, 102-105.	0.8	21
20	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysisâ€”Correction. <i>Journal of Investigative Dermatology</i> , 2021, 141, 177-181.	0.7	5
21	Realâ€world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a singleâ€centre, prospective 1â€year observational cohort study of the first 100 patients treated. <i>British Journal of Dermatology</i> , 2021, 184, 755-757.	1.5	27
22	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 1588-1592.	1.9	4
23	Characteristics modifying response to biological treatments for psoriasis: considering subgroups in network metaâ€analysis. <i>British Journal of Dermatology</i> , 2021, 184, 358-359.	1.5	1
24	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€” Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 281-317.	2.4	84
25	Riskâ€mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€19 pandemic differ by treatment type: a crossâ€sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.5	26
26	Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity. <i>JAMA Dermatology</i> , 2021, 157, 413.	4.1	18
27	Psychosocial aspects of obesity in adults with psoriasis: A systematic review. <i>Skin Health and Disease</i> , 2021, 1, e33.	1.5	8
28	AB0649â€...INFECTION PROFILE OF IMMUNE-MODULATORY DRUGS USED IN AUTOIMMUNE DISEASES: ANALYSIS OF SUMMARY OF PRODUCT CHARACTERISTIC DATA. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1357.2-1358.	0.9	0
29	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021, 39, 467-478.	1.6	9
30	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e496-e498.	2.4	4
31	Defining trajectories of response in patients with psoriasis treated with biologic therapies. <i>British Journal of Dermatology</i> , 2021, 185, 825-835.	1.5	4
32	CYP1A1 Enzymatic Activity Influences Skin Inflammation Via Regulation of the AHR Pathway. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1553-1563.e3.	0.7	34
33	Patient preferences for stratified medicine in psoriasis: a discrete choice experiment. <i>British Journal of Dermatology</i> , 2021, 185, 978-987.	1.5	4
34	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1872-1878.	0.7	4
35	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	2.4	18
36	The power and potential of BIOMAP to elucidate hostâ€microbiome interplay in skin inflammatory diseases. <i>Experimental Dermatology</i> , 2021, 30, 1517-1531.	2.9	5

#	ARTICLE	IF	CITATIONS
37	Enhanced NF- κ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021, 12, 4741.	12.8	23
38	The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross-cohort analyses. <i>British Journal of Dermatology</i> , 2021, 185, 1066-1069.	1.5	10
39	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e627-e637.	3.9	132
40	Dermatology COVID-19 Registries. <i>Dermatologic Clinics</i> , 2021, 39, 575-585.	1.7	12
41	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. <i>JAMA Dermatology</i> , 2021, 157, 66.	4.1	14
42	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
43	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. <i>Scientific Reports</i> , 2021, 11, 23335.	3.3	10
44	Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 714-720.	1.5	54
45	IL-36 Promotes Systemic IFN- γ Responses in Severe Forms of Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 816-826.e3.	0.7	64
46	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 769-778.	2.4	27
47	Developing an online patient education resource for topical therapy: a pilot study. <i>British Journal of Dermatology</i> , 2020, 182, 508-509.	1.5	1
48	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register). <i>Journal of Clinical Investigation</i> , 2020, 130, 5029-5037.	10.1	297
49	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 131.	4.1	110
50	T-cell phenotyping uncovers systemic features of atopic dermatitis and psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1021-1025.e15.	2.9	13
51	P266-IL-4/13 inhibitor dupilumab associated with new onset peripheral axial spondyloarthritis in patients with atopic dermatitis. <i>Rheumatology</i> , 2020, 59, .	1.9	0
52	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020, 107, 539-543.	6.2	44
53	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020, 156, 1216.	4.1	18
54	The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. <i>British Journal of Dermatology</i> , 2020, 183, 981-983.	1.5	2

#	ARTICLE	IF	CITATIONS
55	Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. <i>British Journal of Dermatology</i> , 2020, 183, 638-649.	1.5	54
56	International collaboration and rapid harmonization across dermatologic COVID-19 registries. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e261-e266.	1.2	13
57	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>British Journal of Dermatology</i> , 2020, 183, 294-302.	1.5	85
58	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. <i>British Journal of Dermatology</i> , 2020, 183, 628-637.	1.5	131
59	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020, 13, 400-409.	3.1	9
60	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1440-1448.	2.4	47
61	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 404-406.	1.5	18
62	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2129-2137.	0.7	6
63	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2461-2498.	2.4	149
64	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. <i>Trials</i> , 2020, 21, 158.	1.6	7
65	Risk factors for mental illness in adults with atopic eczema or psoriasis: protocol for a systematic review. <i>BMJ Open</i> , 2020, 10, e038324.	1.9	5
66	In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeks. <i>Annals of Internal Medicine</i> , 2020, 173, JC55.	3.9	2
67	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2019, 180, 329-337.	1.5	36
68	Atopic dermatitis: the skin barrier and beyond. <i>British Journal of Dermatology</i> , 2019, 180, 464-474.	1.5	156
69	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1021-1026.	2.9	165
70	Psoriasis biologics: a new era of choice. <i>Lancet</i> , 2019, 394, 807-808.	13.7	13
71	Morphologic Switch From Psoriasiform to Eczematous Dermatitis After Anti-IL-17 Therapy. <i>JAMA Dermatology</i> , 2019, 155, 1082.	4.1	10
72	Analysis of referral patterns from a tertiary dermatology service to a tertiary rheumatology service in Guyana and St Thomas hospital. <i>Rheumatology</i> , 2019, 58, .	1.9	0

#	ARTICLE	IF	CITATIONS
73	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1235.	4.1	30
74	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	41
75	Prevalence of Advanced Liver Fibrosis in Patients With Severe Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1028.	4.1	17
76	Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. <i>British Journal of Dermatology</i> , 2019, 181, 1068-1070.	1.5	47
77	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1265-1271.	1.5	15
78	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 810-811.	2.9	2
79	Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02. <i>Nature Communications</i> , 2019, 10, 1150.	12.8	82
80	Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. <i>British Journal of Dermatology</i> , 2019, 181, 946-953.	1.5	56
81	Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab. <i>British Journal of Dermatology</i> , 2019, 181, 385-386.	1.5	15
82	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	2.9	128
83	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 1069-1076.	1.5	74
84	Clinical outcomes in patients on secukinumab (Cosentyx [®]) within a specialist psoriasis clinic: a single centre, retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e89-e91.	2.4	3
85	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. <i>Rheumatology</i> , 2019, 58, 144-148.	1.9	24
86	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 115-123.	0.7	60
87	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. <i>British Journal of Dermatology</i> , 2019, 180, 894-901.	1.5	12
88	Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. <i>British Journal of Dermatology</i> , 2019, 181, 256-264.	1.5	14
89	Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2018, 179, 50-53.	1.5	7
90	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 775-784.	0.7	71

#	ARTICLE	IF	CITATIONS
91	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018, 154, 581.	4.1	74
92	Exposure to biological therapies during conception and pregnancy: a systematic review. <i>British Journal of Dermatology</i> , 2018, 178, 95-102.	1.5	40
93	Risk of cancer in patients with psoriasis on biological therapies: a systematic review. <i>British Journal of Dermatology</i> , 2018, 178, 103-113.	1.5	95
94	Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 277-280.	0.9	50
95	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 534-541.	0.7	62
96	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. <i>British Journal of Dermatology</i> , 2018, 178, 1083-1101.	1.5	380
97	Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. <i>Nature Communications</i> , 2018, 9, 5075.	12.8	48
98	Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial. <i>Trials</i> , 2018, 19, 534.	1.6	5
99	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. <i>Trials</i> , 2018, 19, 465.	1.6	15
100	Aldara-induced dermatitis is associated with development of liver fibrosis in mice. <i>British Journal of Dermatology</i> , 2018, 179, 9-10.	1.5	0
101	SAT0189...Dynamics of circulating tn timer during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tn timer assay. , 2018, , .		1
102	Updated guidance for writing a British Association of Dermatologists clinical guideline: the adoption of the GRADE methodology 2016. <i>British Journal of Dermatology</i> , 2017, 176, 44-51.	1.5	29
103	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1646-1654.	0.7	108
104	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. <i>British Journal of Dermatology</i> , 2017, 177, 628-636.	1.5	226
105	Genetic architecture of acne vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1978-1990.	2.4	39
106	European consensus statement on phenotypes of pustular psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1792-1799.	2.4	269
107	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1410-1421.	1.5	24
108	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017, 177, 828-836.	1.5	18

#	ARTICLE	IF	CITATIONS
109	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.5	8
110	An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic target. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	124
111	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1774-1779.	0.9	51
112	Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2644-2646.	0.7	7
113	European S3â€“Guideline on the systemic treatment of psoriasis vulgaris â€“ Update Apremilast and Secukinumab â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1951-1963.	2.4	116
114	Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 7-8.	1.5	8
115	Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2484-2490.	0.7	75
116	Tumour necrosis factor antagonist-induced lupus: a Critically Appraised Topic. <i>British Journal of Dermatology</i> , 2017, 177, 1519-1526.	1.5	6
117	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017, 176, 1297-1307.	1.5	50
118	Acne and Telomere Length: A New Spectrum between Senescence and Apoptosis Pathways. <i>Journal of Investigative Dermatology</i> , 2017, 137, 513-515.	0.7	6
119	Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. <i>British Journal of Dermatology</i> , 2017, 176, 1028-1034.	1.5	88
120	Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. <i>Rheumatology</i> , 2017, 56, 2109-2113.	1.9	70
121	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	2.9	41
122	THU0004â€“...Cross phenotype association mapping of the mhc identifies genetic variants that differentiate psoriatic arthritis from psoriasis. , 2017, , .		0
123	U.K. guidelines for the management of Stevensâ€“Johnson syndrome/toxic epidermal necrolysis in adults 2016. <i>British Journal of Dermatology</i> , 2016, 174, 1194-1227.	1.5	199
124	AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2251-2259.	0.7	128
125	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1584-1591.	0.7	63
126	British Association of Dermatologistsâ€“™ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. <i>British Journal of Dermatology</i> , 2016, 175, 23-44.	1.5	86

#	ARTICLE	IF	CITATIONS
127	Hypercalcaemia-induced kidney injury caused by the vitamin D analogue calcitriol for psoriasis: a note of caution when prescribing topical treatment. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 899-901.	1.3	5
128	Hidradenitis suppurativa: haploinsufficiency of gamma-secretase components does not affect gamma-secretase enzyme activity <i>in vitro</i> . <i>British Journal of Dermatology</i> , 2016, 175, 632-635.	1.5	11
129	UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, e119-e153.	1.0	67
130	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. <i>British Journal of Dermatology</i> , 2015, 173, 510-518.	1.5	87
131	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2015, 135, 2632-2640.	0.7	318
132	European S3 Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - in cooperation with EADV and ICD. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	2.4	353
133	The Role of Yeast in Atopic Dermatitis Revisited: a Critical Appraisal. <i>Current Dermatology Reports</i> , 2015, 4, 228-240.	2.1	4
134	Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2903-2907.	0.7	30
135	Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms. <i>American Journal of Human Genetics</i> , 2015, 96, 104-120.	6.2	163
136	Psoriasis and Cardiometabolic Traits: Modest Association but Distinct Genetic Architectures. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1283-1293.	0.7	56
137	Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2015, 33, 163-177.	3.3	12
138	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2964-2970.	0.7	89
139	IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1067-1070.e9.	2.9	115
140	Generalized Pustular Eruptions: Time to Adapt the Disease Taxonomy to the Genetic Architecture?. <i>Journal of Investigative Dermatology</i> , 2014, 134, 580-581.	0.7	5
141	The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1779.	0.7	1
142	New blisters in a patient treated for Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 63-65.	1.3	1
143	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	3.4	21
144	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. <i>British Journal of Dermatology</i> , 2014, 170, 995-996.	1.5	0

#	ARTICLE	IF	CITATIONS
145	Loss of IL36RN Function Does Not Confer Susceptibility to Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2014, 134, 271-273.	0.7	25
146	Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2014, 170, 1237-1247.	1.5	39
147	Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ ILC3 in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 984-991.	0.7	329
148	Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2014, 171, 267-273.	1.5	52
149	Psoriasis: guidance on assessment and referral. <i>Clinical Medicine</i> , 2014, 14, 178-182.	1.9	12
150	Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris. <i>Nature Communications</i> , 2014, 5, 4020.	12.8	68
151	Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. <i>British Journal of Dermatology</i> , 2014, 171, 17-29.	1.5	72
152	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. <i>American Journal of Human Genetics</i> , 2014, 94, 790-797.	6.2	153
153	A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e131-5.	2.4	63
154	Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. <i>British Journal of Dermatology</i> , 2013, 169, 306-313.	1.5	65
155	Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. <i>British Journal of Dermatology</i> , 2013, 168, 954-967.	1.5	81
156	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.5	130
157	Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1366-1369.	0.7	140
158	Psoriasis and Cardiovascular Disease: Where Is the Risk?. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2308-2311.	0.7	4
159	Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. <i>Journal of Dermatological Treatment</i> , 2013, 24, 38-49.	2.2	25
160	Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2340-2346.	0.7	224
161	Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. <i>British Journal of Dermatology</i> , 2013, 168, 1095-1105.	1.5	23
162	The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2381-2389.	0.7	51

#	ARTICLE	IF	CITATIONS
163	Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1904-1907.	0.7	107
164	The 2012 BSR and BHRP guideline for the treatment of psoriatic arthritis with biologics. <i>Rheumatology</i> , 2013, 52, 1754-1757.	1.9	79
165	Systemic treatment of adult atopic dermatitis. <i>Clinical Medicine</i> , 2012, 12, 172-176.	1.9	13
166	Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 317-322.	1.2	55
167	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	21.4	848
168	Assessment and management of psoriasis: summary of NICE guidance. <i>BMJ</i> , The, 2012, 345, e6712-e6712.	6.0	63
169	Mutations in the Î³-Secretase Genes NCSTN , PSENEN , and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa). <i>Journal of Investigative Dermatology</i> , 2012, 132, 2459-2461.	0.7	126
170	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. <i>British Journal of Dermatology</i> , 2012, 166, 189-195.	1.5	34
171	The British Association of Dermatologistsâ€™ Biologic Interventions Register (BADBIR): design, methodology and objectives. <i>British Journal of Dermatology</i> , 2012, 166, 545-554.	1.5	108
172	Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. <i>British Journal of Dermatology</i> , 2012, 167, 165-173.	1.5	21
173	Infliximab for the treatment of psoriasis in the U.K.: 9â€¦yearsâ€™ experience of infusion reactions at a single centre. <i>British Journal of Dermatology</i> , 2012, 167, 411-416.	1.5	22
174	A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2011, 164, 26-32.	1.5	32
175	Systemic antipsoriatic therapy may reverse endothelial dysfunction: reply from authors. <i>British Journal of Dermatology</i> , 2011, 164, 1398-1398.	1.5	0
176	Psoriasis, cardiovascular disease and flowâ€¦mediated dilatation: reply from authors. <i>British Journal of Dermatology</i> , 2011, 165, 924-925.	1.5	0
177	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 758-764.	2.4	74
178	Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 896-901.	4.7	99
179	Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. <i>American Journal of Human Genetics</i> , 2011, 89, 432-437.	6.2	468
180	Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , 2011, 303, 1-10.	1.9	690

#	ARTICLE	IF	CITATIONS
181	Identification of a Novel Proinflammatory Human Skin-Homing $\text{V}\alpha^39\text{V}\beta^2$ T Cell Subset with a Potential Role in Psoriasis. <i>Journal of Immunology</i> , 2011, 187, 2783-2793.	0.8	301
182	PSENEN and NCSTN Mutations in Familial Hidradenitis Suppurativa (Acne Inversa). <i>Journal of Investigative Dermatology</i> , 2011, 131, 1568-1570.	0.7	103
183	Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1981-1986.	0.7	84
184	The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: A prospective cohort study. <i>Journal of Dermatological Treatment</i> , 2011, 22, 79-85.	2.2	5
185	Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activity. <i>BMJ: British Medical Journal</i> , 2011, 342, d1417-d1417.	2.3	12
186	On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1458-1467.	2.4	33
187	Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. <i>British Journal of Dermatology</i> , 2010, 162, 427-434.	1.5	53
188	Antinuclear antibodies associate with loss of response to antitumour necrosis factor- α therapy in psoriasis: a retrospective, observational study. <i>British Journal of Dermatology</i> , 2010, 162, 780-785.	1.5	76
189	The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. <i>British Journal of Dermatology</i> , 2010, 163, 648-649.	1.5	14
190	Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. <i>British Journal of Dermatology</i> , 2010, 163, 889-892.	1.5	21
191	A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2010, 163, 807-816.	1.5	54
192	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	21.4	918
193	The International Psoriasis Council Presents Top 10 Psoriasis Research Articles for 2010. <i>Psoriasis Forum</i> , 2010, 16a, 44-51.	0.1	0
194	How genetic variation affects patient response and outcome to therapy for psoriasis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 957-966.	3.0	20
195	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. <i>British Journal of Dermatology</i> , 2009, 160, 438-441.	1.5	64
196	Care of patients with psoriasis: an audit of U.K. services in secondary care. <i>British Journal of Dermatology</i> , 2009, 160, 557-564.	1.5	27
197	British Association of Dermatologists'™ guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009, 161, 987-1019.	1.5	412
198	A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: the AGREE-ing™ on a common base for European evidence-based psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 782-787.	2.4	34

#	ARTICLE	IF	CITATIONS
199	Adalimumab for psoriasis patients who are nonresponders to etanercept: open-label prospective evaluation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1394-1397.	2.4	27
200	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	2.4	683
201	Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1925-1929.	0.7	109
202	A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. <i>British Journal of Dermatology</i> , 2008, 159, 942-951.	1.5	71
203	Long-term Safety and Efficacy of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Children. <i>Acta Dermato-Venereologica</i> , 2007, 87, 54-61.	1.3	61
204	British Guidelines on the Use of Biological Therapies for Psoriasis: A Note of Clarification on the Role of Etanercept. <i>Archives of Dermatology</i> , 2007, 143, 1595-6.	1.4	3
205	Polymorphisms in Folate, Pyrimidine, and Purine Metabolism Are Associated with Efficacy and Toxicity of Methotrexate in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1860-1867.	0.7	104
206	Inpatient management of psoriasis: a multicentre service review to establish national admission standards. <i>British Journal of Dermatology</i> , 2007, 158, 266-272.	1.5	15
207	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. <i>British Journal of Dermatology</i> , 2006, 154, 345-352.	1.5	74
208	Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. <i>British Journal of Dermatology</i> , 2006, 155, 160-169.	1.5	49
209	Killed <i>Mycobacterium vaccae</i> suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. <i>Clinical and Experimental Allergy</i> , 2006, 36, 1115-1121.	2.9	35
210	Diffuse plane xanthomatosis and acquired palmoplantar keratoderma in association with myeloma. <i>British Journal of Dermatology</i> , 2006, 152, 286-289.	1.5	19
211	Interaction between Genetic Control of Vascular Endothelial Growth Factor Production and Retinoid Responsiveness in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2006, 126, 453-459.	0.7	105
212	Psoriasis and its management. <i>BMJ: British Medical Journal</i> , 2006, 333, 380-384.	2.3	100
213	Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. <i>British Journal of Dermatology</i> , 2005, 152, 152-154.	1.5	33
214	Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. <i>British Journal of Dermatology</i> , 2005, 152, 444-450.	1.5	124
215	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. <i>British Journal of Dermatology</i> , 2005, 153, 486-497.	1.5	245
216	A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment after First and Repeated Application to Children with Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2005, 124, 695-699.	0.7	82

#	ARTICLE	IF	CITATIONS
217	Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. <i>British Journal of Dermatology</i> , 2004, 151, 492-496.	1.5	56
218	0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. <i>British Journal of Dermatology</i> , 2004, 150, 554-562.	1.5	122
219	Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 539-546.	2.9	230
220	Pharmacogenetics in clinical dermatology. <i>British Journal of Dermatology</i> , 2002, 146, 2-6.	1.5	23
221	A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. <i>British Journal of Dermatology</i> , 2001, 144, 321-327.	1.5	88
222	Guidelines for the management of tinea capitis. <i>British Journal of Dermatology</i> , 2000, 143, 53-58.	1.5	156
223	A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 580-583.	1.3	26
224	Eosinophil infiltration into human skin is antigen-dependent in the late-phase reaction. <i>British Journal of Dermatology</i> , 1996, 134, 997-1004.	1.5	1
225	Eosinophil infiltration into human skin is antigen-dependent in the late-phase reaction. <i>British Journal of Dermatology</i> , 1996, 134, 997-1004.	1.5	8
226	Cell trafficking and role of adhesion molecules in psoriasis. <i>Clinics in Dermatology</i> , 1995, 13, 151-160.	1.6	18
227	Mast cell number and phenotype in chronic idiopathic urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 1995, 96, 360-364.	2.9	85
228	A case of chromoblastomycosis responding to treatment with itraconazole. <i>British Journal of Dermatology</i> , 1993, 128, 436-439.	1.5	30
229	Excess melanocytic nevi in children with renal allografts. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 51-55.	1.2	98
230	Adhesion Molecules in Allergic Inflammation. <i>The American Review of Respiratory Disease</i> , 1993, 148, S75-S78.	2.9	41
231	Cutaneous responses to vasoactive intestinal polypeptide in chronic idiopathic urticaria. <i>Lancet, The</i> , 1992, 339, 91-93.	13.7	39
232	Cutaneous histamine metabolism in chronic urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 1992, 89, 944-950.	2.9	6
233	Clinicopathological features of Chromoblastomycosis—a case report. <i>British Journal of Dermatology</i> , 1992, 127, 82-83.	1.5	0
234	Pitfalls in the determination of diamine oxidase activity. <i>Clinica Chimica Acta</i> , 1991, 201, 89-94.	1.1	3

#	ARTICLE	IF	CITATIONS
235	Polyarteritis nodosa presenting as meningoencephalitis. <i>Journal of the Royal Society of Medicine</i> , 1987, 80, 704-5.	2.0	1
236	A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. <i>Wellcome Open Research</i> , 0, 6, 360.	1.8	8
237	The importance of illness severity and multimorbidity in the association between mental health and body weight in psoriasis: Cross-sectional and longitudinal analysis. <i>Skin Health and Disease</i> , 0, , .	1.5	2
238	The need for clarity on the use of glucocorticoids for people with psoriatic arthritis: A call for consensus. <i>Rheumatology</i> , 0, , .	1.9	0